Disease Severity Modifier in the NICE Single Technology Appraisal of Trastuzumab Deruxtecan: External Assessment Group Perspective

Diarmuid Coughlan (), Oluwatomi Arisa, Katie Thomson, Ge Yu, Fiona Pearson, Ashleigh Kernohan, Sonia Garcia Gonzalez-Moral, Sheila Wallace and Stephen Rice
Additional contact information
Diarmuid Coughlan: Newcastle University
Oluwatomi Arisa: Newcastle University
Katie Thomson: Newcastle University
Ge Yu: Newcastle University
Fiona Pearson: Newcastle University
Ashleigh Kernohan: Newcastle University
Sheila Wallace: Newcastle University
Stephen Rice: Newcastle University

PharmacoEconomics, 2024, vol. 42, issue 1, No 2, 5-9

Date: 2024
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40273-023-01317-z Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:42:y:2024:i:1:d:10.1007_s40273-023-01317-z

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-023-01317-z

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().